$NEO Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.07 up 133.33% YoY
• Reported revenue of $209.25M up 11.42% YoY
• NeoGenomics raised full-year 2026 consolidated revenue guidance to $807M$809M and adjusted EBITDA guidance to approximately $60M; full-year net loss guidance is -$32M-$30M, with adjusted EBITDA approximately 38% above FY 2025.